MedTrace Logo

Assessing the Impact of Clown Therapy in a Palliative Care Unit: A Prospective, Descriptive Study

NCT02610452 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-07-28

No results posted yet for this study

Summary

The main objective of this study was to assess changes in the quality of life of patients in a Palliative Care Unit via the symptoms by the Edmonton Symptom Assessment System (ESAS) before and one hour after the passage of a clown therapist .

Conditions

  • Palliative Care

Interventions

OTHER

Clown therapy

The clowns intervene by twos: a game takes place. 1. The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere. 2. The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state. 3. The original game proposal is adjusted according to mutual empathy with those present. 4. The game is developed on the model of theatrical improvisation: an original creation that has "scenic" quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme. 5. The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Principal Investigators

  • Sylvie Blanchard, MD · Centre Hospitalier Universitaire de Nîmes

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-11-12
Completion
2016-11-12

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02610452 on ClinicalTrials.gov